Exact Mass: 475.3661

Exact Mass Matches: 475.3661

Found 53 metabolites which its exact mass value is equals to given mass value 475.3661, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

(7Z,10Z,13Z,16Z)-Docosatetraenoylcarnitine

3-[(7Z,10Z,13Z,16Z)-Docosa-7,10,13,16-tetraenoyloxy]-4-(trimethylammonio)butanoic acid

C29H49NO4 (475.3661)


(7Z,10Z,13Z,16Z)-Docosatetraenoylcarnitine is an acylcarnitine. More specifically, it is an (7Z,10Z,13Z,16Z)-docosa-7,10,13,16-tetraenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (7Z,10Z,13Z,16Z)-Docosatetraenoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (7Z,10Z,13Z,16Z)-Docosatetraenoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Adrenoylcarnitine

(9Z,12Z,15Z,18Z)-2-[1-hydroxy-2-(trimethylazaniumyl)ethyl]-3-oxotetracosa-9,12,15,18-tetraenoate

C29H49NO4 (475.3661)


   

Holantosine F

Holantosine F

C28H45NO5 (475.3298)


   

N-Lignoceroyl Taurine

N-Lignoceroyl Taurine

C26H53NO4S (475.3695)


   

2-tetracosanamidoethanesulfonic acid

2-tetracosanamidoethanesulfonic acid

C26H53NO4S (475.3695)


   

CAR 22:4

3-[(7Z,10Z,13Z,16Z)-docosa-7,10,13,16-tetraenoyloxy]-4-(trimethylammonio)butanoate;all-cis-7,10,13,16-docosatetraenoylcarnitine

C29H49NO4 (475.3661)


   

NAT 24:0

N-tetracosanoyl taurine

C26H53NO4S (475.3695)


   

TRIOCTYLPROPYLAMMONIUM BROMIDE

TRIOCTYLPROPYLAMMONIUM BROMIDE

C27H58BrN (475.3752)


   

(2-hydroxyethyl)dimethyl[3-[(1-oxooctadecyl)amino]propyl]ammonium nitrate

(2-hydroxyethyl)dimethyl[3-[(1-oxooctadecyl)amino]propyl]ammonium nitrate

C25H53N3O5 (475.3985)


   
   

NAGly 16:4/10:0

NAGly 16:4/10:0

C28H45NO5 (475.3298)


   

(10Z,13Z,16Z,19Z)-N-(1,3-dihydroxyoctan-2-yl)docosa-10,13,16,19-tetraenamide

(10Z,13Z,16Z,19Z)-N-(1,3-dihydroxyoctan-2-yl)docosa-10,13,16,19-tetraenamide

C30H53NO3 (475.4025)


   

(10Z,13Z,16Z)-N-[(E)-1,3-dihydroxyoct-4-en-2-yl]docosa-10,13,16-trienamide

(10Z,13Z,16Z)-N-[(E)-1,3-dihydroxyoct-4-en-2-yl]docosa-10,13,16-trienamide

C30H53NO3 (475.4025)


   

(9Z,12Z)-N-[(4E,8E)-1,3-dihydroxydodeca-4,8-dien-2-yl]octadeca-9,12-dienamide

(9Z,12Z)-N-[(4E,8E)-1,3-dihydroxydodeca-4,8-dien-2-yl]octadeca-9,12-dienamide

C30H53NO3 (475.4025)


   

(6Z,9Z,12Z,15Z)-N-(1,3-dihydroxydodecan-2-yl)octadeca-6,9,12,15-tetraenamide

(6Z,9Z,12Z,15Z)-N-(1,3-dihydroxydodecan-2-yl)octadeca-6,9,12,15-tetraenamide

C30H53NO3 (475.4025)


   

(Z)-N-[(4E,8E,12E)-1,3-dihydroxytetradeca-4,8,12-trien-2-yl]hexadec-9-enamide

(Z)-N-[(4E,8E,12E)-1,3-dihydroxytetradeca-4,8,12-trien-2-yl]hexadec-9-enamide

C30H53NO3 (475.4025)


   

(8Z,11Z,14Z,17Z)-N-(1,3-dihydroxydecan-2-yl)icosa-8,11,14,17-tetraenamide

(8Z,11Z,14Z,17Z)-N-(1,3-dihydroxydecan-2-yl)icosa-8,11,14,17-tetraenamide

C30H53NO3 (475.4025)


   

(7Z,10Z,13Z)-N-[(E)-1,3-dihydroxytetradec-4-en-2-yl]hexadeca-7,10,13-trienamide

(7Z,10Z,13Z)-N-[(E)-1,3-dihydroxytetradec-4-en-2-yl]hexadeca-7,10,13-trienamide

C30H53NO3 (475.4025)


   

(4Z,7Z,10Z,13Z)-N-(1,3-dihydroxytetradecan-2-yl)hexadeca-4,7,10,13-tetraenamide

(4Z,7Z,10Z,13Z)-N-(1,3-dihydroxytetradecan-2-yl)hexadeca-4,7,10,13-tetraenamide

C30H53NO3 (475.4025)


   

(9Z,12Z)-N-[(4E,8E)-1,3-dihydroxytrideca-4,8-dien-2-yl]heptadeca-9,12-dienamide

(9Z,12Z)-N-[(4E,8E)-1,3-dihydroxytrideca-4,8-dien-2-yl]heptadeca-9,12-dienamide

C30H53NO3 (475.4025)


   

(Z)-N-[(4E,8E,12E)-1,3-dihydroxyheptadeca-4,8,12-trien-2-yl]tridec-9-enamide

(Z)-N-[(4E,8E,12E)-1,3-dihydroxyheptadeca-4,8,12-trien-2-yl]tridec-9-enamide

C30H53NO3 (475.4025)


   

(9Z,12Z)-N-[(4E,8E)-1,3-dihydroxytetradeca-4,8-dien-2-yl]hexadeca-9,12-dienamide

(9Z,12Z)-N-[(4E,8E)-1,3-dihydroxytetradeca-4,8-dien-2-yl]hexadeca-9,12-dienamide

C30H53NO3 (475.4025)


   

(9Z,12Z,15Z)-N-[(E)-1,3-dihydroxydodec-4-en-2-yl]octadeca-9,12,15-trienamide

(9Z,12Z,15Z)-N-[(E)-1,3-dihydroxydodec-4-en-2-yl]octadeca-9,12,15-trienamide

C30H53NO3 (475.4025)


   

(11Z,14Z,17Z)-N-[(E)-1,3-dihydroxydec-4-en-2-yl]icosa-11,14,17-trienamide

(11Z,14Z,17Z)-N-[(E)-1,3-dihydroxydec-4-en-2-yl]icosa-11,14,17-trienamide

C30H53NO3 (475.4025)


   

(E)-3-hydroxy-2-(tridecanoylamino)dodec-4-ene-1-sulfonic acid

(E)-3-hydroxy-2-(tridecanoylamino)dodec-4-ene-1-sulfonic acid

C25H49NO5S (475.3331)


   

3-hydroxy-2-[[(Z)-tetradec-9-enoyl]amino]undecane-1-sulfonic acid

3-hydroxy-2-[[(Z)-tetradec-9-enoyl]amino]undecane-1-sulfonic acid

C25H49NO5S (475.3331)


   

(E)-3-hydroxy-2-(undecanoylamino)tetradec-4-ene-1-sulfonic acid

(E)-3-hydroxy-2-(undecanoylamino)tetradec-4-ene-1-sulfonic acid

C25H49NO5S (475.3331)


   

(E)-3-hydroxy-2-(pentadecanoylamino)dec-4-ene-1-sulfonic acid

(E)-3-hydroxy-2-(pentadecanoylamino)dec-4-ene-1-sulfonic acid

C25H49NO5S (475.3331)


   

3-hydroxy-2-[[(Z)-pentadec-9-enoyl]amino]decane-1-sulfonic acid

3-hydroxy-2-[[(Z)-pentadec-9-enoyl]amino]decane-1-sulfonic acid

C25H49NO5S (475.3331)


   

(E)-3-hydroxy-2-(tetradecanoylamino)undec-4-ene-1-sulfonic acid

(E)-3-hydroxy-2-(tetradecanoylamino)undec-4-ene-1-sulfonic acid

C25H49NO5S (475.3331)


   

(E)-2-(decanoylamino)-3-hydroxypentadec-4-ene-1-sulfonic acid

(E)-2-(decanoylamino)-3-hydroxypentadec-4-ene-1-sulfonic acid

C25H49NO5S (475.3331)


   

(E)-2-(dodecanoylamino)-3-hydroxytridec-4-ene-1-sulfonic acid

(E)-2-(dodecanoylamino)-3-hydroxytridec-4-ene-1-sulfonic acid

C25H49NO5S (475.3331)


   

3-hydroxy-2-[[(Z)-tridec-9-enoyl]amino]dodecane-1-sulfonic acid

3-hydroxy-2-[[(Z)-tridec-9-enoyl]amino]dodecane-1-sulfonic acid

C25H49NO5S (475.3331)


   

(Z)-N-[(4E,8E,12E)-1,3-dihydroxyhexadeca-4,8,12-trien-2-yl]tetradec-9-enamide

(Z)-N-[(4E,8E,12E)-1,3-dihydroxyhexadeca-4,8,12-trien-2-yl]tetradec-9-enamide

C30H53NO3 (475.4025)


   

(Z)-N-[(4E,8E,12E)-1,3-dihydroxypentadeca-4,8,12-trien-2-yl]pentadec-9-enamide

(Z)-N-[(4E,8E,12E)-1,3-dihydroxypentadeca-4,8,12-trien-2-yl]pentadec-9-enamide

C30H53NO3 (475.4025)


   

(Z)-N-[(4E,8E,12E)-1,3-dihydroxyoctadeca-4,8,12-trien-2-yl]dodec-5-enamide

(Z)-N-[(4E,8E,12E)-1,3-dihydroxyoctadeca-4,8,12-trien-2-yl]dodec-5-enamide

C30H53NO3 (475.4025)


   

(Z)-N-[(4E,8E,12E)-1,3-dihydroxyheptadeca-4,8,12-trien-2-yl]tridec-8-enamide

(Z)-N-[(4E,8E,12E)-1,3-dihydroxyheptadeca-4,8,12-trien-2-yl]tridec-8-enamide

C30H53NO3 (475.4025)


   

(Z)-N-[(4E,8E,12E)-1,3-dihydroxytetradeca-4,8,12-trien-2-yl]hexadec-7-enamide

(Z)-N-[(4E,8E,12E)-1,3-dihydroxytetradeca-4,8,12-trien-2-yl]hexadec-7-enamide

C30H53NO3 (475.4025)


   

(4Z,7Z)-N-[(4E,8E)-1,3-dihydroxytetradeca-4,8-dien-2-yl]hexadeca-4,7-dienamide

(4Z,7Z)-N-[(4E,8E)-1,3-dihydroxytetradeca-4,8-dien-2-yl]hexadeca-4,7-dienamide

C30H53NO3 (475.4025)


   

(7Z,10Z,13Z,16Z)-docosatetraenoylcarnitine

(7Z,10Z,13Z,16Z)-docosatetraenoylcarnitine

C29H49NO4 (475.3661)


An O-acylcarnitine having (7Z,10Z,13Z,16Z)-docosatetraenoyl as the acyl substituent.

   

N-tetracosanoyltaurine

N-tetracosanoyltaurine

C26H53NO4S (475.3695)


A fatty acid-taurine conjugate derived from tetracosanoic acid.

   

NA-2AAA 22:4(7Z,10Z,13Z,16Z)

NA-2AAA 22:4(7Z,10Z,13Z,16Z)

C28H45NO5 (475.3298)


   

NA-DOPA 19:1(9Z)

NA-DOPA 19:1(9Z)

C28H45NO5 (475.3298)


   

NA-Dopamine 22:0

NA-Dopamine 22:0

C30H53NO3 (475.4025)


   

NA-His 22:1(11Z)

NA-His 22:1(11Z)

C28H49N3O3 (475.3774)


   

NA-Taurine 24:0

NA-Taurine 24:0

C26H53NO4S (475.3695)


   
   
   

Cer 14:0;O2/16:4

Cer 14:0;O2/16:4

C30H53NO3 (475.4025)


   

ST 26:2;O3;Gly

ST 26:2;O3;Gly

C28H45NO5 (475.3298)


   

ST 27:1;O2;Gly

ST 27:1;O2;Gly

C29H49NO4 (475.3661)


   

Cer(30:4)

Cer(d12:0_18:4)

C30H53NO3 (475.4025)


Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved

   

(2r,3s,4r,6s)-6-{[(1s,2r,5s,7s,10r,11r,14r,17s,18s)-10,17-dimethyl-16,21-dioxahexacyclo[15.3.1.0¹,¹⁴.0²,¹¹.0⁵,¹⁰.0¹⁴,¹⁸]henicosan-7-yl]oxy}-4-methoxy-2-methyloxan-3-amine

(2r,3s,4r,6s)-6-{[(1s,2r,5s,7s,10r,11r,14r,17s,18s)-10,17-dimethyl-16,21-dioxahexacyclo[15.3.1.0¹,¹⁴.0²,¹¹.0⁵,¹⁰.0¹⁴,¹⁸]henicosan-7-yl]oxy}-4-methoxy-2-methyloxan-3-amine

C28H45NO5 (475.3298)